PharmaAccess – Milestones
Before PharmaAccess was started, the founders envisioned their brand achieving several milestones over time. As they strived to accomplish those goals, they developed a network of reliable partners and enhanced their service portfolio. This is how they uncovered new potential and achieved their goals within a short span of time – something that we take great pride in.
It was due to our team’s brilliance, hard work, experience and efforts that we grew as a company. From ensuring companies penetrate the foreign markets to exploiting the opportunities in the GCC market by giving the exposure every company need, PharmaAccess has made a mark. We have helped many companies in their regulatory affairs, relation management, sales and salesforce management, and medical management, among other healthcare business areas.
PharmaAccess’s Achievements
The major achievement that PharmaAccess boasts is its team of experienced, seasoned professionals. PharmaAccess has a team of well-trained professionals who have helped successfully establish brands in the pharmaceutical industry to meet their desired goals.
Using effective strategies, we uncover new opportunities in the pharmaceutical world and develop further as a successful brand.
OUR MILESTONES include, but are not limited to
SALES GROWTH In The Past 5 Years
Sales in Units
Sales in Value
Get in touch with us today to find out more!
Get in touch with us to find out more today!
Key Highlights of 2020
PharmaAccess created a mobile application for their customers to help them abide to social distancing procedures during the pandemic while ensuring effective communication channels remain open with their customers. This mobile application has helped them maintain their strong growth in 2020 despite the inability to physically meet most of their customers.
United Arab Emirates
- Total growth – 19% in units
- Total Cinfa MS% growing – 4% increased to 5.1%
- Atorvastatin growth – 54% in units
- Olmesartan range – 24% MS in the molecule
- Olmesartan range – 0.34 RMS from innovator
- Ulcerbrex keep growing – at 17%
- Coxicel 0.7 RMS of Innovator
- 1 Million units sold in 2020
Saudi Arabia
- 4% MS from total ED segment in less than one year with 40% market share of vardenafil molecule
- 73 RMS of Innovator (market leader)
Kuwait
- Total growth 23% in units
- Total Cinfa MS% growing 0.6% reached 9.1%
- Ziquin ranking number 1 in levofloxacin molecule
- Ulcerbrex ranking number 1 rabeprazole
Qatar
- Total growth 53% in units
- Atorcor growth 65% in units